Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOXEL in Advanced Cholangiocarcinoma
NCT00350961Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, oxaliplatin and capecitabine in cholangiocarcinoma (CCA), gallbladder carcinoma and ampullary carcinoma, sponsored by Rigshospitalet. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate. Started Jun 2004; status: completed.
02
Drugs
gemcitabineoxaliplatincapecitabine
03
Conditions
cholangiocarcinoma (CCA)gallbladder carcinomaampullary carcinoma
Beyond the preview
Go deeper on NCT00350961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00350961.